Serum is not required for ex vivo IFN-γ ELISPOT: A collaborative study of different protocols from the European CIMT Immunoguiding Program

Cancer Immunology, Immunotherapy

Volumn 59, Issue 4, 2010, Pages 619-627

  Mander, A ^a   Gouttefangeas, C ^b   Ottensmeier, C ^a   Welters, M J P ^c   Low, L ^a   Van Der Burg, S H ^c   Britten, C M ^d  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Elispot; Free; Harmonization; Multicenter study; Serum; T cell enumeration

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSPOT ASSAY; EUROPE; EX VIVO STUDY; GAMMA INTERFERON ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; LABORATORY TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; CELL CULTURE; CELL SURVIVAL; COMPARATIVE STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; IMMUNOLOGY; METHODOLOGY; MONONUCLEAR CELL; STANDARD; STATISTICS;

GAMMA INTERFERON; PEPTIDE FRAGMENT; VIRUS ANTIGEN;

ANTIGENS, VIRAL; CELL SURVIVAL; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; LABORATORY TECHNIQUES AND PROCEDURES; LEUKOCYTES, MONONUCLEAR; PEPTIDE FRAGMENTS; REFERENCE STANDARDS;

EID: 77449158159     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0814-4     Document Type: Article

References (22)

1. van der Burg SH (2008) Therapeutic vaccines in cancer: moving from, immunomonitoring to immunoguiding. Expert Rev Vaccines 7:1-5 (Pubitemid 351357961)
2. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumen stein B, Sacks N, Keilholz U, Nichol G (1997) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1-15
3. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Hakansson L (2009) Improving the efficacy of cancer immunotherapy. Eur J Cancer 45:1424-1431
4. Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A (2007) Toward the harmonization of immune monitoring in clinical trials: Quo vadis? Cancer Immunol Immunother 57:285-288
5. Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D'souza MP (2005) Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses 21:68-81
6. Hanekom. WA, Dockrell HM, Ottenhoff TH, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, and Fruth UJ (2008) Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5:e145
7. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Hakansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM (2008) A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA. taskforce on immunotherapy biomarkers". J Transl Med 6:81
8. Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A (2008) Results and harmonization guidelines from two largescale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium. (CVC/SVI). Cancer Immunol Immunother 57:303-315 (Pubitemid 350295382)
9. Britten CM, Janetzki S, Ben Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P (2009) Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Cancer Immunol Immunother 58:1701-1713
10. Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor SP, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T, van der Burg SH (2008) The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 57:289-302
11. Martinuzzi E, Scotto M, Enee E, Brezar V, Ribeil JA, van Endert P, Mallone R (2008) Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection. J Immunol Methods 333:61-70
12. Ahmad S, Sundaramoorthy E, Arora R, Sen S, Karthikeyan G, Sengupta S (2009) Progressive degradation of serum samples limits proteomic biomarker discovery. Anal Biochem 394:237-242
13. Gislefoss RE, GrimsrudTK, Morkrid L (2008) Long-term stability of serum components in the Janus Serum Bank. Scand J Clin Lab Invest 68:402-409
14. Zhang W, Caspell R, Karulin AY, Ahmad M, Haicheur N, Abdelsalam A, Johannesen K, Vignard V, Dudzik P, Georgakopoulou K, Mihaylova A, Silina K, Aptsiauri N, Adams V, Lehmann PV, McArdle S (2009) ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring- even in the hands of inexperienced investigators. J Immunotoxicol 6:227-234
15. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJM, Old LJ, Romero P, Hoos A, Davis MM (2009) "MIATA"minimal information about T cell assays. Immunity 31:527-528
16. Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, Morse MA, Clay TM, Lyerly HK, Bhatia S, Ghanekar SA, Maino VC, Delarosa C, Disis ML (2008) Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 9:1-9
17. Janetzki S, Cox JH, Oden N, Ferrari G (2005) Standardization and validation issues of the ELISPOT assay. Methods Mol Biol 302:51-86
18. Mander A, Chowdhury F, Low L, Ottensmeier CH (2009) Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. Cancer Immunol Immunother 58:789-800
19. Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A (2009) Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells. Cancer Immunol Immunother (ePub ahead of print)
20. Weinberg A, Song LY, Wilkening C, Sevin A, Blais B, Louzao R, Stein D, Defechereux P, Durand D, Riedel E, Raftery N, Jesser R, Brown B, Keller MF, Dickover R, McFarland E, Fenton T (2009) Optimization and limitations of use of cryopreserved peripheral blood mononuclear cells for functional and phenotypic T-cell characterization. Clin Vaccine Immunol 16:1176-1186
21. Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM, Antonello J, Caulfield MJ (2007) Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin Vaccine Immunol 14:527-537
22. Elliott P, Peakman TC (2008) The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol 37:234-244 (Pubitemid 351494195)